Short report: A phase one safety study of Lactobacillus reuteri conducted in the peruvian amazon: Observations from the field

Richard A. Oberhelman, Margaret N. Kosek, Pablo Peñataro-Yori, Maribel Paredes-Olórtegui, Eamonn Connolly

Research output: Contribution to journalArticlepeer-review

Abstract

Clinical research on probiotics presents challenging issues for researchers, regulators, and funding agencies, and these issues become more complex when United States federally funded research is conducted outside the United States. Here, we describe the design and results of a Phase I safety study of Lactobacillus reuteri DSM 17938 conducted as a community-based trial under the Food and Drug Administration Investigative New Drug (FDA IND) program in a small town in the Peruvian Amazon. Forty-five healthy adults 18 to 65 years of age were randomized in a 2:1 ratio to receive either Lactobacillus reuteri 108 organisms once daily for 5 days or an identical appearing placebo. Results showed no evidence of invasive infection resulting from probiotic administration and no differences between groups. Although we encountered several challenges in conducting an FDA-approved safety trial in this setting, the rigorously collected contextually relevant data will be very valuable to support later Phase II/III studies of L. reuteri for use in similar settings.

Original languageEnglish (US)
Pages (from-to)777-780
Number of pages4
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume90
Issue number4
DOIs
StatePublished - Apr 2014

ASJC Scopus subject areas

  • Parasitology
  • Virology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Short report: A phase one safety study of Lactobacillus reuteri conducted in the peruvian amazon: Observations from the field'. Together they form a unique fingerprint.

Cite this